Eris Lifesciences Ltd · NSE:ERIS
Eris Lifesciences — Investor Presentation (February 2022)
32 slides from Eris Lifesciences's investor presentation, Feb 2, 2022
Slide 1: Corporate presentation filing letter to BSE and NSE
Date: 2nd February, 2022 To To BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza Dalal Street Bandra Kurla Complex Mumbai- 400001 Bandra (E) Mumbai-400051 Security Code: 540596 Symbol: ERIS SUBJECT: CORPORATE PRESENTATION Dear Sir/Madam, Pursuant to the re
Slide 2: Eris Lifesciences Corporate Presentation February 2022
Eris Lifesciences Corporate Presentation February 2022
Slide 3: Business Highlights
Business Highlights Only Indian listed pharmaco with a pure-play Revenues up 2x and PAT up 2.6x in last 5 years Domestic Branded Formulations model Revenue PAT Youngest among India’s Top-25 domestic branded formulation pharmacos 12,119 Chronic and Sub-Chronic therapies account for 5,970 92% of
Slide 4: Financial Snapshot
Financial Snapshot FY 21 9M FY 22 ₹ mn ₹ mn ₹ mn ₹ mn 12,119 4,306 10,411 3,881 Op Revenue 12.8% EBITDA 16.9% Op Revenue 11.5% EBITDA 15.5% yoy growth yoy growth yoy growth yoy growth ₹ mn ₹ mn ₹ 3,551 26.16 3,258 PAT 19.8% EPS 21.0% PAT 13.6% yoy growth yoy growth yoy growth Dividends as % of net p
Slide 5: Eris has Grown at Twice the Market Rate from Pre-Covid Levels
Eris has Grown at Twice the Market Rate from Pre-Covid Levels Eris has outperformed the IPM by 710 bps from the 19.3% pre-Covid base 13.9% 13.1% 11.8% 11.7% 11.5% 10.5% 9.9% 8.7% 8.5% 6.8% IPM exl. IPCA ERIS LS MANKIND TORRENT INTAS MACLEODS SUN MICRO ARISTO EMCURE Covid % Acute molecules Therapy 47
Slide 6: Sustained growth in core therapies accounting for 91% of Revenue
Sustained growth in core therapies accounting ` for 91% of Revenue ORAL ANTI-DIABETES : 32% of Eris CARDIOLOGY : 27% of Eris VMN: 20% of Eris 18.3% 12.3% 12.8% over IPM 7.5% over IPM 16.6% 5.1% over IPM 7.2% 9.1% 6.0% IPM Eris IPM Eris IPM Eris CNS: 8% of Eris WOMEN’S HEALTH: 4% of Eris Eris has g
Slide 7: Chronic and Sub-Chronic focus with emphasis on Cardio-Metabolic
Chronic and Sub-Chronic focus with emphasis on Cardio-Metabolic Contribution of Chronic + Subchronic vs. Acute Therapy-wise composition of revenue Oral Diabetes Care 32% Others 4% Women’s Health 4% Chronic & 84% Sub-chronic 92% Gastro Intestinal 5% CNS 8% Cardiac Care 27% Acute 16% 8% VMN 20% MAT De
Slide 8: Eris Enjoys a Strong Position in the ~INR 9,000 Crore Oral Anti-Diabetes Market
Eris Enjoys a Strong Position in the ~ INR 9,000 Crore Oral Anti-Diabetes Market Eris has built a full-service presence in Oral Anti-Diabetes therapy Eris ranks in Oral Anti-Diabetes therapy with high market ranks in latest generation molecules (DPP4 and SGLT2 inhibitors) By Revenue* Total # Rx** Rx
Slide 9: Highlights of the joint venture with MJ Biopharm
Highlights of the joint venture with MJ Biopharm • Leading position in Indian oral anti-diabetes • Proven capabilities in developing advanced biological formulations from preclinical through to • Strong credibility with Diabetologists/ Phase III and regulatory approval Endocrinologists and Key Opini
Slide 10: Top-15 Power Brands Portfolio Contribute ~73% of Revenue
Top-15 Power Brands Portfolio Contribute ~ 73% of Revenue Our Top 15 Mother Brands contribute ~ 73% of our revenue Blockbuster additions to power brand portfolio in the last two years MAT Dec’21 Sales (₹ mn) Market share ` 2,798 6% 1,436 4% • Crossed INR 60+ crore of annual revenue 1,317 7% • Rank #
Slide 11: Eris Enjoys High Prescription Ranks among Super-Specialists
Eris Enjoys High Prescription Ranks among Super-Specialists Eris Prescription Ranks* among leading Doctor Specialties 3 4 3 DIABETOLOGISTS CARDIOLOGISTS NEUROLOGISTS 4 5 CONSULTING GASTROENTEROLOGISTS PHYSICIANS 10 Source: SMSRC MAT Oct 2021 │ * In the represented market
Slide 12: Eris Continues to Create Value from Acquisitions
Eris Continues to Create Value from Acquisitions Indian Branded Formulation Business of Strides Shasun (2017) Zomelis (2019) Discontinued tail-end brands; focused attention on Top-5 Consistently ranked #1 among all (95+) Gx versions of brands in the portfolio (Renerve, Raricap, Ginkocer, Serlift
Slide 13: Three Pillars of Our Market Engagement
Three Pillars of Our Market Engagement The core focus of our market engagement is to enable clinicians to improve clinical outcomes in patients through timely and precision diagnosis and treatment 1 2 3 Dissemination of latest Generation of scientific knowledge Patient Care initiatives actionable sc
Slide 14: Leading the Digital Dissemination of Scientific Knowledge
1. Leading the Digital Dissemination of Scientific Knowledge since the Start of the Pandemic • As a prominent stakeholder in the enhancement of scientific knowledge, Eris has conducted ~3,200+ digital (group) interactions since the start of the pandemic covering 47,000+ doctors • Discussion topics i
Slide 15: Pioneering India-Centric Studies – The India Heart Study
2. Pioneering India-Centric Studies to Generate Actionable Scientific Evidence – The India Heart Study IHS Methodology IHS Revealed Expert Speak The investigators examined the blood 42% of the participants were White-coat hypertensives get pressure of 18,918 participants with misdiagnosed and were u
Slide 16: Patient Care – Driving Precision Diagnosis and Better Disease Management
3. Patient Care – Driving Precision Diagnosis and Better Disease Management Our Patient Care Initiatives (PCI) platform enables us to bring cutting- edge healthcare solutions to our patients through the involvement and Number of Patients Screened Number of Patients Screened Number of Patients Scre
Slide 17: Our Manufacturing Infrastructure
Our Manufacturing Infrastructure WHO-GMP manufacturing 74% of revenue (in FY21) and WHO GMP facility in Guwahati, Assam facility in Guwahati, Assam 81% of revenue (in 9M FY22) 100,000 Built-up area (sq. ft) from products manufactured at 345+ Products manufactured The Guwahati facility Capacity utili
Slide 18: Pan-India Sales Presence and Distribution Network
Pan-India Sales Presence and Distribution Network Stockists Region-wise sales distribution (H1 FY22) 11 Super Stockists 1 7 81 South , 39% 26 44 58 East, 10% 122 207 49 59 2 3 91 28 145 131 34 97 159 127 5 North , 22% 165 West, 29% 101 2 Central Warehouses 244 23 Sales Depots 137 2,133 Stockists 5,0
Slide 19: Board of Directors
Board of Directors • Eight-member Board of Directors, comprising of four Executive Directors and four Independent Directors, Amit Bakshi Krishnakumar V Inderjit Singh Negi Kaushal Shah including two women directors Chairman and Executive Director & Executive Director Executive Director Managing Dire
Slide 20: Lifestyle Diseases Uptrend – A Large Market Opportunity
Lifestyle Diseases Uptrend – A Large Market Opportunity Expected prevalence of CVD in India Significant increase in prevalence of non-communicable 69 diseases (NCDs) in India; share of heart disease and metabolic disorders projected to expand in the years to come 29 22 19 6 8 India is called the
Slide 21: Enduring Pillars of Our Business Strategy
Hence the Enduring Pillars of Our Business Strategy CHRONIC AND SUB-CHRONIC THERAPIES 20
Slide 22: Key Growth Drivers (1/2)
Key Growth Drivers (1/2) • Our business model of building strong and sustainable brands has enabled us to significantly 1 Expansion of outperform the market during the pandemic period (Eris CAGR of ~14% vs. IPM CAGR of power-brands’ ~7%*) when MR-Doctor interactions were severely constrained for sev
Slide 23: Key Growth Drivers (2/2)
Key Growth Drivers (2/2) Expansion of • We continue to make good progress in expanding our coverage of Specialists and Consulting 3 physician Physicians in line with our expectations coverage Therapeutic • We are investing in diversification opportunities in high-growth areas like CNS 4 diversificat
Slide 24: Safe Harbour Statement
Safe Harbour Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and the underlying assumptions
Slide 25: Eris Lifesciences Ltd.
Eris Lifesciences Ltd. CORPORATE OFFICE: Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad, Gujarat 380054 CIN: L24232GJ2007PLC049867 Website : www.eris.co.in IR Contact Kruti Raval kruti@erislifesciences.com 24
Slide 26: Appendix
Appendix Appendix Er s 25
Slide 27: Business Structure and Holdings
Business Structure and Holdings Eris Lifesciences Limited Promoters Aprica Healthcare Limited 10.4% Earlier known as UTH Public 52.7% Healthcare Limited Eris M. J. Biopharm 13.3% Private Limited FPI Earlier known as Kinedex Healthcare Private Limited DIIs 23.2% Eris Therapeutics Limited Promoter sha
Slide 28: Financial Summary (1/2)
Financial Summary (1/2) P&L Summary FY17 FY18 FY19 FY20 FY21 9M FY22 Revenue 7,495 8,556 9,822 10,741 12,119 10,411 Gross Profit 6,449 7,215 8,285 9,025 9,736 8,444 Gross Profit Margin (%) 86.0% 84.3% 84.4% 84.0% 80.3% 81.1% Operating EBITDA 2,691 3,220 3,449 3,684 4,306 3,881 Operating EBITDA Margi
Slide 29: Financial Summary (2/2)
Financial Summary (2/2) FY17 FY18 FY19 FY20 FY21 9M FY22 BS Summary Mar'17 Mar'18 Mar'19 Mar'20 Mar'21 9M FY22 Margin (%) Share Capital 138 138 138 136 136 136 Gross Margin 86.0% 84.3% 84.4% 84.0% 80.3% 81.1% Reserves 5,534 8,476 11,368 12,828 15,628 18,135 EBITDA Margin 35.9% 37.6% 35.1% 34.3% 35.5
Slide 30: Key Brands in Oral Diabetes Care
Key Brands in Oral Diabetes Care Therapy wide presence in Oral Diabetes Care with power brands holding high ranks in newer generation fast- growing molecules (DPP4 and SGLT2 inhibitors) Sulfonylurea rank 6 in the ~4,700 cr Glimepiride and combinations market Glimisave MV rank 2 in Glimeperide + Vogl
Slide 31: Key Brands in Cardiovascular and VMN Therapies
Key Brands in Cardiovascular and VMN Therapies High rank in Anti-Hypertensives: the largest segment of Cardiac Care rank 5 in the ~3,700 cr Telmisartan and combinations market Eritel CH rank 5 in the Telmisartan + Chlorthalidone market Eritel LN rank 2 in the Telmisartan + Cilnidipine market rank 5
Slide 32: Thank You
Eris THANK YOU Eris Lifesciences
Eris Lifesciences — Investor Presentation (February 2022) on 6ix